J Korean Med Assoc.  2019 Jan;62(1):18-24. 10.5124/jkma.2019.62.1.18.

Diagnosis of pulmonary tuberculosis

• Jhun BW
• Huh HJ
• Koh WJ

• KMID: 2431991
• DOI: http://doi.org/10.5124/jkma.2019.62.1.18

Abstract

The incidence and prevalence of pulmonary tuberculosis (TB) in South Korea remain high despite the fact that South Korea is a high-income country, and pulmonary TB is an important public health issue in terms of both morbidity and mortality. Thus, rapid diagnosis and management of active pulmonary TB are crucial for effective TB control, which can help to prevent the transmission of TB and the occurrence of new TB cases. However, because the clinical and radiological presentations of pulmonary TB may occasionally be nonspecific, identification of causative microorganisms using laboratory tests is the most important diagnostic method. Recently-developed microbiological and molecular techniques are commonly employed in current clinical practice. In particular, advances in liquid culture system, line probe assays, and Xpert MTB/RIF assay have reduced the identification time and facilitate the identification of drug-resistance TB. However, as various tests have both advantages and limitations, physicians should be aware of the principles underpinning the tests when interpreting the results. Thus, the clinical and radiological characteristics of pulmonary TB and several diagnostic laboratory tests that we describe below will aid physicians in diagnosing pulmonary TB efficiently.

Keyword

Diagnosis; Tuberculosis, pulmonary; Drug resistance

MeSH Terms

Diagnosis*
Drug Resistance
Incidence
Korea
Methods
Mortality
Prevalence
Public Health
Tuberculosis, Pulmonary*

Reference

1. World Health Organization. Global tuberculosis report 2018 [Internet]. Geneva: World Health Organization;2018. cited 2018 Dec 18. Available from: https://www.who.int/tb/publications/global_report/en/.

2. Cho KS. Tuberculosis control in the Republic of Korea. Health Soc Welf Rev. 2017; 37:179–212.

3. Kim JH, Yim JJ. Achievements in and challenges of tuberculosis control in South Korea. Emerg Infect Dis. 2015; 21:1913–1920.

4. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015; 372:2127–2135.

5. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, Ginsberg A, Swaminathan S, Spigelman M, Getahun H, Menzies D, Raviglione M. Tuberculosis. Nat Rev Dis Primers. 2016; 2:16076.

6. Lee SH. Tuberculosis infection and latent tuberculosis. Tuberc Respir Dis (Seoul). 2016; 79:201–206.

7. Joint Committee for the Revision of Korean Guidelines for Tuberculosis. Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. 3rd ed. Cheongju: Korea Centers for Disease Control and Prevention;2017.

8. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med. 2013; 368:745–755.

9. Dheda K, Barry CE 3rd, Maartens G. Tuberculosis. Lancet. 2016; 387:1211–1226.

10. World Health Organization. Chest radiography in tuberculosis detection [Internet]. Geneva: World Health Organization;2016. cited 2018 Dec 18. Available from: https://www.who.int/tb/publications/chest-radiography/en/.

11. Jeong YJ, Lee KS. Pulmonary tuberculosis: up-to-date imaging and management. AJR Am J Roentgenol. 2008; 191:834–844.

12. Nachiappan AC, Rahbar K, Shi X, Guy ES, Mortani Barbosa EJ Jr, Shroff GS, Ocazionez D, Schlesinger AE, Katz SI, Hammer MM. Pulmonary tuberculosis: role of radiology in diagnosis and management. Radiographics. 2017; 37:52–72.

13. Jeong YJ, Lee KS, Yim JJ. The diagnosis of pulmonary tuberculosis: a Korean perspective. Precis Future Med. 2017; 1:77–87.

14. Shen GH, Tsao TC, Kao SJ, Lee JJ, Chen YH, Hsieh WC, Hsu GJ, Hsu YT, Huang CT, Lau YJ, Tsao SM, Hsueh PR. Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions. Int J Antimicrob Agents. 2012; 39:201–205.

15. Gafoor K, Patel S, Girvin F, Gupta N, Naidich D, Machnicki S, Brown KK, Mehta A, Husta B, Ryu JH, Sarosi GA, Franquet T, Verschakelen J, Johkoh T, Travis W, Raoof S. Cavitary lung diseases: a clinical-radiologic algorithmic approach. Chest. 2018; 153:1443–1465.

16. Ketai L, Currie BJ, Holt MR, Chan ED. Radiology of chronic cavitary infections. J Thorac Imaging. 2018; 33:334–343.

17. Ryu YJ, Koh WJ, Daley CL. Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians' perspectives. Tuberc Respir Dis (Seoul). 2016; 79:74–84.

18. Kwon YS, Koh WJ. Diagnosis and treatment of nontuberculous mycobacterial lung disease. J Korean Med Sci. 2016; 31:649–659.

19. Jhun BW, Jeon K, Eom JS, Lee JH, Suh GY, Kwon OJ, Koh WJ. Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis. Med Mycol. 2013; 51:811–817.

20. Jhun BW, Jung WJ, Hwang NY, Park HY, Jeon K, Kang ES, Koh WJ. Risk factors for the development of chronic pulmonary aspergillosis in patients with nontuberculous mycobacterial lung disease. PLoS One. 2017; 12:e0188716.

21. Im JG, Itoh H. Tree-in-bud pattern of pulmonary tuberculosis on thin-section CT: pathological implications. Korean J Radiol. 2018; 19:859–865.

22. Lee KS, Hwang JW, Chung MP, Kim H, Kwon OJ. Utility of CT in the evaluation of pulmonary tuberculosis in patients without AIDS. Chest. 1996; 110:977–984.

23. Korea Centers for Disease Control and Prevention. Korea National Institute of Health. Korean Society of Clinical Micorbiology. Manual of laboratory tests for tuberculosis [Internet]. Cheongju: Korea Centers for Disease Control and Prevention;2013. cited 2018 Dec 18. Available from: https://www.gidcc.or.kr/wp-content/uploads/2016/12/2013년-결핵검사지침.pdf.

24. Siddiqi K, Lambert ML, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. Lancet Infect Dis. 2003; 3:288–296.

25. Behr MA, Warren SA, Salamon H, Hopewell PC, Ponce de Leon A, Daley CL, Small PM. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 1999; 353:444–449.

26. Mixides G, Shende V, Teeter LD, Awe R, Musser JM, Graviss EA. Number of negative acid-fast smears needed to adequately assess infectivity of patients with pulmonary tuberculosis. Chest. 2005; 128:108–115.

27. Mase SR, Ramsay A, Ng V, Henry M, Hopewell PC, Cunningham J, Urbanczik R, Perkins MD, Aziz MA, Pai M. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis. 2007; 11:485–495.

28. Davis JL, Cattamanchi A, Cuevas LE, Hopewell PC, Steingart KR. Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2013; 13:147–154.

29. Kim N, Yi J, Chang CL. Recovery rates of non-tuberculous mycobacteria from clinical specimens are increasing in Korean tertiary-care hospitals. J Korean Med Sci. 2017; 32:1263–1267.

30. Ko RE, Moon SM, Ahn S, Jhun BW, Jeon K, Kwon OJ, Huh HJ, Ki CS, Lee NY, Koh WJ. Changing epidemiology of nontuberculous mycobacterial lung diseases in a tertiary referral hospital in Korea between 2001 and 2015. J Korean Med Sci. 2018; 33:e65.

31. Yoon HJ, Choi HY, Ki M. Nontuberculosis mycobacterial infections at a specialized tuberculosis treatment centre in the Republic of Korea. BMC Infect Dis. 2017; 17:432.

32. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K. ATS Mycobacterial Diseases Subcommittee. American Thoracic Society. Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175:367–416.

33. Forbes BA, Hall GS, Miller MB, Novak SM, Rowlinson MC, Salfinger M, Somoskovi A, Warshauer DM, Wilson ML. Practice guidelines for clinical microbiology laboratories: mycobacteria. Clin Microbiol Rev. 2018; 01. 31. [Epub]. DOI: 10.1128/CMR.00038-17.

34. Koh WJ, Ko Y, Kim CK, Park KS, Lee NY. Rapid diagnosis of tuberculosis and multidrug resistance using a MGIT 960 system. Ann Lab Med. 2012; 32:264–269.

35. Li S, Liu B, Peng M, Chen M, Yin W, Tang H, Luo Y, Hu P, Ren H. Diagnostic accuracy of Xpert MTB/RIF for tuberculosis detection in different regions with different endemic burden: A systematic review and meta-analysis. PLoS One. 2017; 12:e0180725.

36. Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J. 2016; 48:516–525.

37. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014; (1):CD009593.

38. Kohli M, Schiller I, Dendukuri N, Dheda K, Denkinger CM, Schumacher SG, Steingart KR. Xpert(R) MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database Syst Rev. 2018; 8:CD012768.

39. Lee HS, Kee SJ, Shin JH, Kwon YS, Chun S, Lee JH, Won EJ, Choi HJ, Kim SH, Shin MG, Shin JH, Suh SP. Xpert MTB/RIF assay as a substitute for smear microscopy in an intermediate burden setting. Am J Respir Crit Care Med. 2018; 09. 25:[Epub]. DOI: 10.1164/rccm.201804-0654OC.

40. Weyer K, Mirzayev F, Migliori GB, Van Gemert W, D'Ambrosio L, Zignol M, Floyd K, Centis R, Cirillo DM, Tortoli E, Gilpin C, de Dieu Iragena J, Falzon D, Raviglione M. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J. 2013; 42:252–271.

41. Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, Hall SL, Chakravorty S, Cirillo DM, Tukvadze N, Bablishvili N, Stevens W, Scott L, Rodrigues C, Kazi MI, Joloba M, Nakiyingi L, Nicol MP, Ghebrekristos Y, Anyango I, Murithi W, Dietze R, Lyrio Peres R, Skrahina A, Auchynka V, Chopra KK, Hanif M, Liu X, Yuan X, Boehme CC, Ellner JJ, Denkinger CM. study team. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018; 18:76–84.

42. Arend SM, van Soolingen D. Performance of Xpert MTB/RIF Ultra: a matter of dead or alive. Lancet Infect Dis. 2018; 18:8–10.

43. Bahr NC, Nuwagira E, Evans EE, Cresswell FV, Bystrom PV, Byamukama A, Bridge SC, Bangdiwala AS, Meya DB, Denkinger CM, Muzoora C, Boulware DR. ASTRO-CM Trial Team. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. Lancet Infect Dis. 2018; 18:68–75.

44. Joh JS, Lee CH, Lee JE, Park YK, Bai GH, Kim EC, Han SK, Shim YS, Yim JJ. The interval between initiation of anti-tuberculosis treatment in patients with culture-positive pulmonary tuberculosis and receipt of drug-susceptibility test results. J Korean Med Sci. 2007; 22:26–29.

45. World Health Organization. Use of liquid TB culture and drug susceptibility testing (DST) in low and medium income setting [Internet]. Geneva: World Health Organization;2007. cited 2018 Dec18. Available from: http://www.stoptb.org/wg/gli/assets/documents/EGM%20report_Use%20of%20Liquid%20Culture%20Media.pdf.

46. World Health Organization. The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin [Internet]. Geneva: World Health Organization;2016. cited 2018 Dec18. Available from: https://www.who.int/tb/publications/molecular-test-resistance/en/.

47. Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C, Hanna D, Kim PS, Liwski R, Zignol M, Gilpin C, Niemann S, Denkinger CM, Fleming J, Warren RM, Crook D, Posey J, Gagneux S, Hoffner S, Rodrigues C, Comas I, Engelthaler DM, Murray M, Alland D, Rigouts L, Lange C, Dheda K, Hasan R, Ranganathan UDK, McNerney R, Ezewudo M, Cirillo DM, Schito M, Köser CU, Rodwell TC. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. Eur Respir J. 2017; 50:1701354.

48. Theron G, Peter J, Richardson M, Warren R, Dheda K, Steingart KR. GenoType(R) MTBDRsl assay for resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev. 2016; 9:CD010705.